ONO Pharmaceutical Co. Ltd.

06/05/2024 | Press release | Distributed by Public on 06/04/2024 20:05

Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First Line Treatment[...]

 This material is intended to notify the press release issued on June 4 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.